Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Articles|June 9, 2023
A Look at Climate Change and Mental Health
Author(s)Psychiatric Times Editors
A wide variety of mental health concerns are related to climate change. Here is some recent coverage of these issues in Psychiatric Times®.
Advertisement
Advertisement
Related to this article
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
2
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
3
Dosing MDD Therapies in Medically Complex Patients: Metabolism and Interactions
4
Podcast: Using Antipsychotic Plasma Levels to Guide Schizophrenia Treatment With Jonathan M. Meyer, MD
5